June 10, 2025

How Family Adventures, Precision Oncology, and Living Purposefully Bring Balance to the Life of Charu Aggarwal, MD, MPH, FASCO

At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she can’t explain where the idea came from. She just knows the desire to ...

The ASCO Post

June 06, 2025

Tarlatamab Improves Survival in Resistant Lung Cancer

A multinational phase 3 trial found that tarlatamab significantly improved overall survival and reduced toxicity compared with standard chemotherapy in patients with small-cell lung cancer after progression on platinum-based therapy.

Conexiant

June 05, 2025

SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC

Although the SWOG S2302 Pragmatica-Lung trial did not achieve its primary endpoint of improved overall survival with the combination of ramucirumab and pembrolizumab compared with standard-of-care tre...

The ASCO Post

June 04, 2025

Big Tobacco's Medical Research Infiltrates Journals

Investigation reveals tobacco-funded studies appear in top medical journals despite industry bans, as companies invest billions in pharmaceutical subsidiaries.

Conexiant

June 04, 2025

Chemo Killed Her. A Test Might've Saved Her.

A fatal enzyme deficiency turned a common chemo drug toxic. With testing available—but rarely used—are clinicians missing a lifesaving step?

KFF Health News

June 03, 2025

FDA Grants Breakthrough Status to Shield Test

The methylation-based blood assay is designed for screening multiple cancer types.

Conexiant

May 28, 2025

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are availa...

The ASCO Post

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 23, 2025

Early-Phase Trial Shows Activity and Safety of Zongertinib in Previously Treated HER2-Mutant NSCLC

Zongertinib, an investigational oral, HER2-selective, EGFR-sparing tyrosine kinase inhibitor, elicited durable responses and demonstrated clinical benefit in patients with advanced, previously treated...

The ASCO Post